potassium voltage-gated channel subfamily D member 2
RGD ID:
68393
Description:
Enables A-type (transient outward) potassium channel activity and voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential. Involved in several processes, including cellular response to hypoxia; cellular response to mechanical stimulus; and potassium ion transmembrane transport. Located in several cellular components, including T-tubule; neuronal cell body membrane; and perinuclear endoplasmic reticulum. Part of voltage-gated potassium channel complex. Is active in glutamatergic synapse and postsynaptic membrane. Orthologous to human KCND2 (potassium voltage-gated channel subfamily D member 2); PARTICIPATES IN excitatory synaptic transmission pathway; alfentanil pharmacodynamics pathway; bupivacaine pharmacodynamics pathway; INTERACTS WITH 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased secretion of Lactic Acid, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased secretion of Lactic Acid
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased import of Glucose, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased import of Glucose
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate
[bisphenol A co-treated with Estradiol] results in decreased expression of KCND2 mRNA, [bisphenol A co-treated with Testosterone] results in decreased expression of KCND2 mRNA
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA, [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased import of Glucose, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased import of Glucose
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased import of Glucose, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased import of Glucose
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased secretion of Lactic Acid, [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased secretion of Lactic Acid
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA, [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
Expression and distribution of Kv4 potassium channel subunits and potassium channel interacting proteins in subpopulations of interneurons in the basolateral amygdala.
Post-transcriptional gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents.
Localization of Kv4.2 and KChIP2 in lipid rafts and modulation of outward K+ currents by membrane cholesterol content in rat left ventricular myocytes.
in the left ventricle the mRNA level displays transmural gradient of the voltage-gated transient outward current density which impacts on cardiac functions such as contractility and impulse conduction
in the left ventricle the mRNA level displays transmural gradient of the voltage-gated transient outward current density which impacts on cardiac functions such as contractility and impulse conduction
in the left ventricle the mRNA level displays transmural gradient of the voltage-gated transient outward current density which impacts on cardiac functions such as contractility and impulse conduction
in the left ventricle the mRNA level displays transmural gradient of the voltage-gated transient outward current density which impacts on cardiac functions such as contractility and impulse conduction
in the left ventricle the mRNA level displays transmural gradient of the voltage-gated transient outward current density which impacts on cardiac functions such as contractility and impulse conduction
